Can we accurately project risk for over-diagnosis and over-treatment?

There is an interesting new article just published in the Journal of the National Cancer Institute describing a nomogram designed to estimate risk for over-diagnosis of men diagnosed with prostate cancer. … READ MORE …

Genomics, prostate cancer, and biomarker development

A number of readers may be interested in an article by Yadav et al. in the January issue of AUA News, entitled “Genomics at the forefront of biomarker development for prostate cancer detection and therapeutics.” … READ MORE …

Pre-diagnostic aspirin use and prostate cancer-related mortality

An article just published in Renal & Urology News states that “Men who take aspirin doses above 75 mg have a significantly reduced risk of death from prostate cancer … compared with men who do not take aspirin.” … READ MORE …

No decrease in mortality rate of newly diagnosed men with metastatic prostate cancer

A newly published paper in the journal Cancer has indicated that, here in the USA, although overall prostate cancer mortality has declined by ~ 40 percent during the past 25 years, there has been no significant decrease in the mortality rate among men who have evident metastatic prostate cancer at time of diagnosis. … READ MORE …

EAU updates guidelines on screening, diagnosis, and management of localized prostate cancer

The European Association of Urology (EAU) has just updated its guideline document “EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent”. … READ MORE …

Does statin therapy really extend survival of men diagnosed with prostate cancer?

An analysis of another large cohort of prostate cancer patients (this time from the United Kingdom) has again suggested that there is a reduction in the risk of prostate cancer-specific mortality for patients who are treated with statins after their initial diagnosis with prostate cancer. … READ MORE …

Eligibility criteria for active surveillance among men with low-risk prostate cancer

As regular readers of this blog will be aware, the urology group at Johns Hopkins in Baltimore has, for the past several years, had one of the most restrictive sets of criteria for eligibility for active surveillance as an appropriate method for the management of men initially diagnosed with low- and very low-risk prostate cancer. … READ MORE …

New prospective study supports baseline PSA testing for men in 40s

According to a newly published, prospective study in the Journal of Urology, a research team at the Mayo Clinic has confirmed prior reports (based on retrospective data) that a baseline PSA in men aged between 40 and 49 years can be used to categorize men into low and higher prostate cancer risk groups. … READ MORE …

Prostate cancer risk profiles among Asian Americans

We really know remarkably little about prostate cancer risk profiles among the heterogeneous members of the male Asian-American community (although there are data suggesting that Asian-American prostate cancer patients tend to present with higher grade and later stage disease than Caucasian Americans). … READ MORE …

Epidemiology, genetics, and risk for (aggressive) prostate cancer

A couple of papers presented in the past few days at meetings of the American Association for Cancer Research (AACR) and the American Society for Human Genetics (ASHG) provide us with interesting (if potentially confusing) information about risk for a diagnosis of prostate cancer. … READ MORE …

The PSA screening controversy: two new pro/con presentations

The “New” Prostate Cancer InfoLink finds it fascinating how, while sticking to their guns about the value of “screening” healthy men for risk of prostate cancer, the two differing groups of advocates (those “for/pro” screening and those “against/con” its) are still failing to appropriately emphasize that they are using the word “screening” with differing intent. … READ MORE …

Nomograms projecting risk for upgrading in lower-risk forms of prostate cancer

We are starting to see the development of nomograms that can be used to project the risk for future upgrading of men who are diagnosed with very low- and low-risk prostate cancer and who initially meet criteria for active surveillance as a first-line management strategy. … READ MORE …

From Amsterdam yesterday: European perspectives on the PSA screening issue

A report on the Medscape Oncology web site, published late yesterday, discusses two presentations given yesterday at the European Cancer Conference 2013, currently being held in Amsterdam. … READ MORE …

Mediterranean diet and overall mortality after diagnosis with non-metastatic prostate cancer

An article in European Urology has shown that a heart-healthy, “Mediterranean” diet lowers the overall mortality of men diagnosed with prostate cancer. However, the study also shows that this type of diet has no impact on risk for a diagnosis of advanced or lethal prostate cancer or on prostate cancer progression or prostate cancer-specific mortality after diagnosis. … READ MORE …

A real molecular signature that predicts with accuracy for indolent prostate cancer?

In a new paper entitled “A molecular signature predictive of indolent prostate cancer”, a research team at Columbia University Medical Center in New York report the identification of a three-gene “signature” that may be able, accurately, to differentiate between indolent and more aggressive forms of prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,074 other followers